Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.
de Haas V, Breunis WB, Dee R, Verhagen OJ, Kroes W, van Wering ER, van Dongen JJ, van den Berg H, van der Schoot CE. de Haas V, et al. Among authors: van dongen jj, van den berg h, van der schoot ce, van wering er. Br J Haematol. 2002 Jan;116(1):87-93. doi: 10.1046/j.1365-2141.2002.03228.x. Br J Haematol. 2002. PMID: 11841400 Free article.
Immunoglobulin kappa deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR.
van der Velden VH, Willemse MJ, van der Schoot CE, Hählen K, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van der schoot ce, van wering er. Leukemia. 2002 May;16(5):928-36. doi: 10.1038/sj.leu.2402475. Leukemia. 2002. PMID: 11986956
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH, Jacobs DC, Wijkhuijs AJ, Comans-Bitter WM, Willemse MJ, Hählen K, Kamps WA, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er. Leukemia. 2002 Aug;16(8):1432-6. doi: 10.1038/sj.leu.2402636. Leukemia. 2002. PMID: 12145681
Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.
Brüggemann M, van der Velden VH, Raff T, Droese J, Ritgen M, Pott C, Wijkhuijs AJ, Gökbuget N, Hoelzer D, van Wering ER, van Dongen JJ, Kneba M. Brüggemann M, et al. Among authors: van der velden vh, van dongen jj, van wering er. Leukemia. 2004 Apr;18(4):709-19. doi: 10.1038/sj.leu.2403263. Leukemia. 2004. PMID: 14961040
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ; European Study Group on MRD detection in ALL (ESG-MRD-ALL). van der Velden VH, et al. Among authors: van dongen jj, van der schoot ce. Leukemia. 2007 Apr;21(4):604-11. doi: 10.1038/sj.leu.2404586. Epub 2007 Feb 8. Leukemia. 2007. PMID: 17287850
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.
Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, Vossen JM, Versluys B, Egeler RM, van Tol MJ, Putter H, Révész T, van Dongen JJ, van der Velden VH, Schilham MW. Lankester AC, et al. Among authors: van der velden vh, van dongen jj, van tol mj, van wering er. Leukemia. 2010 Aug;24(8):1462-9. doi: 10.1038/leu.2010.133. Epub 2010 Jun 10. Leukemia. 2010. PMID: 20535148
Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia.
Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V, Veerman AJ, van Kessel AG, Hoogerbrugge PM, Kuiper RP, van Dongen JJ. Waanders E, et al. Among authors: van der velden vh, van reijmersdal sv, van dongen jj, van leeuwen fn, van der schoot ce, van kessel ag. Leukemia. 2011 Feb;25(2):254-8. doi: 10.1038/leu.2010.275. Epub 2010 Nov 19. Leukemia. 2011. PMID: 21102428
Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia.
Denys B, van der Sluijs-Gelling AJ, Homburg C, van der Schoot CE, de Haas V, Philippé J, Pieters R, van Dongen JJ, van der Velden VH. Denys B, et al. Among authors: van der velden vh, van dongen jj, van der schoot ce, van der sluijs gelling aj. Leukemia. 2013 Mar;27(3):635-41. doi: 10.1038/leu.2012.231. Epub 2012 Aug 16. Leukemia. 2013. PMID: 22945774
Detection of minimal residual disease in acute leukemia patients.
van Dongen JJ, Szczepański T, de Bruijn MA, van den Beemd MW, de Bruin-Versteeg S, Wijkhuijs JM, Tibbe GJ, van Gastel-Mol EJ, Groeneveld K, Hooijkaas H. van Dongen JJ, et al. Among authors: van den beemd mw, van gastel mol ej. Cytokines Mol Ther. 1996 Jun;2(2):121-33. Cytokines Mol Ther. 1996. PMID: 9384697 Review.
581 results